Highlights From the Circulation Family of Journals

Area of Science:

• Cardiology
• Medical Technology
• Genetics

Background:

• Atrial fibrillation, microvascular dysfunction, and atherosclerosis progression are key cardiovascular concerns.
• The DAPA-HF trial investigated dapagliflozin's effect on heart failure.
• Stroke quality initiatives aim to improve patient outcomes.

Purpose of the Study:

• To explore novel methods for predicting atrial fibrillation using AI.
• To investigate the interplay of alcohol consumption, genetics, and atrial fibrillation.
• To assess ranolazine's efficacy in treating microvascular dysfunction.
• To evaluate the association between positron emission tomography findings and coronary calcification.
• To report on the Target: Stroke quality initiative.
• To analyze dapagliflozin's benefits in heart failure patients based on disease duration.

Main Methods:

• An artificial intelligence algorithm was applied to sinus rhythm ECGs.
• Genetic predisposition was considered in evaluating alcohol intake's effect on atrial fibrillation.
• A randomized trial assessed ranolazine treatment for microvascular dysfunction.
• 18F-sodium florid activity via PET was measured.
• Data from the Target: Stroke initiative were reported.
• A DAPA-HF substudy analyzed dapagliflozin's efficacy across heart failure duration cohorts.

Main Results:

• AI algorithms independently predicted atrial fibrillation from ECGs.
• Alcohol intake's association with atrial fibrillation varied by genetic predisposition.
• Ranolazine treatment was evaluated for microvascular dysfunction.
• Baseline 18F-sodium florid activity correlated with incident coronary calcification.
• The Target: Stroke initiative's outcomes were presented.
• Dapagliflozin demonstrated benefits across different heart failure durations in the DAPA-HF substudy.

Conclusions:

• AI holds potential for early atrial fibrillation detection.
• Genetic factors modify the cardiovascular risks associated with alcohol.
• Ranolazine may be a viable treatment for microvascular dysfunction.
• PET imaging can predict future coronary calcification.
• Quality improvement initiatives are crucial for stroke care.
• Dapagliflozin offers consistent benefits in heart failure management regardless of duration.